Cargando…

Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy

PURPOSE: To develop an Eclipse plug‐in (MLC_MODIFIER) that automatically modifies control points to expose fiducials obscured by MLC during VMAT, thereby facilitating tracking using periodic MV/kV imaging. METHOD: Three‐dimensional fiducial tracking was performed during VMAT by pairing short‐arc (3°...

Descripción completa

Detalles Bibliográficos
Autores principales: Happersett, Laura, Wang, Ping, Zhang, Pengpeng, Mechalakos, James, Li, Guang, Eley, Eleanor, Zelefsky, Michael, Mageras, Gig, Damato, Antonio L., Hunt, Margie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560246/
https://www.ncbi.nlm.nih.gov/pubmed/31116478
http://dx.doi.org/10.1002/acm2.12614
_version_ 1783425933544259584
author Happersett, Laura
Wang, Ping
Zhang, Pengpeng
Mechalakos, James
Li, Guang
Eley, Eleanor
Zelefsky, Michael
Mageras, Gig
Damato, Antonio L.
Hunt, Margie
author_facet Happersett, Laura
Wang, Ping
Zhang, Pengpeng
Mechalakos, James
Li, Guang
Eley, Eleanor
Zelefsky, Michael
Mageras, Gig
Damato, Antonio L.
Hunt, Margie
author_sort Happersett, Laura
collection PubMed
description PURPOSE: To develop an Eclipse plug‐in (MLC_MODIFIER) that automatically modifies control points to expose fiducials obscured by MLC during VMAT, thereby facilitating tracking using periodic MV/kV imaging. METHOD: Three‐dimensional fiducial tracking was performed during VMAT by pairing short‐arc (3°) MV digital tomosynthesis (DTS) images to triggered kV images. To evaluate MLC_MODIFIER efficacy, two cohorts of patients were considered. For first 12 patients, plans were manually edited to expose one fiducial marker. Next for 15 patients, plans were modified using MLC_MODIFIER script. MLC_MODIFIER evaluated MLC apertures at appropriate angles for marker visibility. Angles subtended by control points were compressed and low‐dose “imaging” control points were inserted and exposed one marker with 1 cm margin. Patient's images were retrospectively reviewed to determine rate of MV registration failures. Failure categories were poor DTS image quality, MLC blockage of fiducials, or unknown reasons. Dosimetric differences in rectum, bladder, and urethra D1 cc, PTV maximum dose, and PTV dose homogeneity (PTV HI) were evaluated. Statistical significance was evaluated using Fisher's exact and Student's t test. RESULT: Overall MV registration failures, failures due to poor image quality, MLC blockage, and unknown reasons were 33% versus 8.9% (P < 0.0001), 8% versus 6.4% (P < 0.05), 13.6% versus 0.1% (P < 0.0001), and 7.6% versus 2.4% (P < 0.0001) for manually edited and MLC_MODIFIER plans, respectively. PTV maximum and HI increased on average from unmodified plans by 2.1% and 0.3% (P < 0.004) and 22.0% and 3.3% (P < 0.004) for manually edited and MLC_MODIFIED plans, respectively. Changes in bladder, rectum, and urethra D1CC were similar for each method and less than 0.7%. CONCLUSION: Increasing fiducial visibility via an automated process comprised of angular compression of control points and insertion of additional “imaging” control points is feasible. Degradation of plan quality is minimal. Fiducial detection and registration success rates are significantly improved compared to manually edited apertures.
format Online
Article
Text
id pubmed-6560246
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65602462019-06-17 Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy Happersett, Laura Wang, Ping Zhang, Pengpeng Mechalakos, James Li, Guang Eley, Eleanor Zelefsky, Michael Mageras, Gig Damato, Antonio L. Hunt, Margie J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: To develop an Eclipse plug‐in (MLC_MODIFIER) that automatically modifies control points to expose fiducials obscured by MLC during VMAT, thereby facilitating tracking using periodic MV/kV imaging. METHOD: Three‐dimensional fiducial tracking was performed during VMAT by pairing short‐arc (3°) MV digital tomosynthesis (DTS) images to triggered kV images. To evaluate MLC_MODIFIER efficacy, two cohorts of patients were considered. For first 12 patients, plans were manually edited to expose one fiducial marker. Next for 15 patients, plans were modified using MLC_MODIFIER script. MLC_MODIFIER evaluated MLC apertures at appropriate angles for marker visibility. Angles subtended by control points were compressed and low‐dose “imaging” control points were inserted and exposed one marker with 1 cm margin. Patient's images were retrospectively reviewed to determine rate of MV registration failures. Failure categories were poor DTS image quality, MLC blockage of fiducials, or unknown reasons. Dosimetric differences in rectum, bladder, and urethra D1 cc, PTV maximum dose, and PTV dose homogeneity (PTV HI) were evaluated. Statistical significance was evaluated using Fisher's exact and Student's t test. RESULT: Overall MV registration failures, failures due to poor image quality, MLC blockage, and unknown reasons were 33% versus 8.9% (P < 0.0001), 8% versus 6.4% (P < 0.05), 13.6% versus 0.1% (P < 0.0001), and 7.6% versus 2.4% (P < 0.0001) for manually edited and MLC_MODIFIER plans, respectively. PTV maximum and HI increased on average from unmodified plans by 2.1% and 0.3% (P < 0.004) and 22.0% and 3.3% (P < 0.004) for manually edited and MLC_MODIFIED plans, respectively. Changes in bladder, rectum, and urethra D1CC were similar for each method and less than 0.7%. CONCLUSION: Increasing fiducial visibility via an automated process comprised of angular compression of control points and insertion of additional “imaging” control points is feasible. Degradation of plan quality is minimal. Fiducial detection and registration success rates are significantly improved compared to manually edited apertures. John Wiley and Sons Inc. 2019-05-22 /pmc/articles/PMC6560246/ /pubmed/31116478 http://dx.doi.org/10.1002/acm2.12614 Text en © 2019 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Happersett, Laura
Wang, Ping
Zhang, Pengpeng
Mechalakos, James
Li, Guang
Eley, Eleanor
Zelefsky, Michael
Mageras, Gig
Damato, Antonio L.
Hunt, Margie
Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy
title Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy
title_full Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy
title_fullStr Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy
title_full_unstemmed Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy
title_short Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy
title_sort developing a mlc modifier program to improve fiducial detection for mv/kv imaging during hypofractionated prostate volumetric modulated arc therapy
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560246/
https://www.ncbi.nlm.nih.gov/pubmed/31116478
http://dx.doi.org/10.1002/acm2.12614
work_keys_str_mv AT happersettlaura developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT wangping developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT zhangpengpeng developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT mechalakosjames developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT liguang developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT eleyeleanor developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT zelefskymichael developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT magerasgig developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT damatoantoniol developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy
AT huntmargie developingamlcmodifierprogramtoimprovefiducialdetectionformvkvimagingduringhypofractionatedprostatevolumetricmodulatedarctherapy